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Abstract: Bacterial meningitis (BM) is a severe disease caused by various bacterial pathogens. Toll-like
receptors (TLRs) protect humans from invading pathogens. In this study, we determined whether
single nucleotide polymorphisms (SNPs) of TLR4 and TLR9 are associated with susceptibility to and
outcome of BM in Angolan children. Samples were taken from 241 patients and 265 age-matched
ethnic controls. The SNPs TLR4 rs4986790 (896A > G) and TLR9 rs187084 (−1486T > C) were
determined by high-resolution melting analysis (HRMA). The frequency of variant genotypes in
TLR4 was significantly higher in patients with Haemophilus influenzae meningitis than controls (odds
ratio (OR), 2.5; 95% confidence interval (CI), 1.2–5.4; p = 0.021), whereas the frequency of variant
genotypes in TLR9 was significantly lower in patients with H. influenzae meningitis than controls
(OR, 0.4; 95% CI, 0.2–0.9; p = 0.036). No such differences were found with other causative pathogens,
such as Streptococcus pneumoniae and Neisseria meningitidis. At the time of discharge, patients with
meningitis caused by Gram-negative bacteria who were carriers of variant TLR4 genotypes had a
higher risk of ataxia (OR, 12.91; 95% CI, 1.52–109.80; p = 0.019) and other neurological sequelae
(OR, 11.85; 95% CI, 1.07–131.49; p = 0.044) than those with the wild-type TLR4 genotype. Our study
suggests an association between H. influenzae meningitis and genetic variation between TLR4 and
TLR9 in Angolan children.
Keywords: TLR4; TLR9; gene polymorphisms; meningitis; Haemophilus influenzae; HRMA;
children; Angola
1. Introduction
Bacterial meningitis (BM) is a life-threatening infectious disease. Even with early diagnosis
and proper treatment, the fatality rate of BM ranges from 5% to 10% in developed countries and up
to 50% in low-and middle-income countries. It is estimated that approximately 1–2 million cases
of BM occur a year [1], with neonates particularly susceptible. Survivors of meningitis are at an
increased risk of neurological sequelae, such as learning and behavioral disorders, deafness, paresis,
and severe encephalopathy [2]. The most common prerequisite for BM is nasopharyngeal colonization
and bacteremia, where bacteria can spread from blood to cerebrospinal fluid (CSF). The pathogens
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can infect the central nervous system (CNS) by crossing the blood–CSF barrier, invading the CSF
directly through a skull fracture, or from a focal infection (e.g., the nasal sinuses) to the subarachnoid
space [2–4].
BM is caused by various bacteria such as Streptococcus pneumoniae, Neisseria meningitidis,
and Haemophilus influenzae. H. influenzae is still one of the most common causes of BM in
non-industrialized countries. This is due to the lack of effective vaccinations, which have virtually
eliminated H. influenzae type b meningitis in industrialized countries [5]. Both H. influenzae and
N. meningitidis are Gram-negative bacteria carried in the nasopharynx. H. influenzae is a common
causative agent of BM in young children [6,7]. Around 10% of people, mostly school-aged children,
carry N. meningitidis in their nasopharynx, and N. meningitidis is the main cause of BM in children and
young adults. N. meningitidis causes epidemics, particularly in sub-Saharan Africa (the “meningitis
belt”). Pneumococcal nasopharyngeal carriage is common in the general population and affects people
of all ages. S. pneumoniae causes the most severe disease in both young and old people [2,8–10].
Routine immunizations in Angola include the pentavalent vaccine (i.e., diphtheria–
tetanus–pertussis (DTP), hepatitis B, and H. influenzae type b), which was introduced in 2006, and the
13-valent pneumococcal vaccine (PCV13), which was introduced in 2013 [11]. Both are administered
at 2, 4, and 6 months of age. The current estimates of the coverage of three doses of DTP vaccine in
children in Angola range from 48% to 84% [12,13], while estimates for PCV13 vaccination rates range
from 59% to 82% [11,12].
The number of children with BM has been decreasing in the Paediatric Hospital of Luanda
following the introduction of routine childhood pentavalent vaccination in 2006. In particular,
the number of BM cases due to H. influenzae type b has dropped by 86% in the Paediatric Hospital [14].
In 2004, before the use of PCV13 in Angola, there were 93 cases of pneumococcal meningitis identified
in children in this hospital; however, our one-year study found 43 cases of pneumococcal meningitis,
indicating a large decline of BM caused by S. pneumoniae in the post-PCV13 period [5].
Pathogen-sensing Toll-like receptors (TLRs) are key components of innate and adaptive immunity.
To date, ten TLRs have been identified in humans (i.e., TLR1 to TLR10). TLR4 is expressed on the
cell surface and recognizes the lipopolysaccharides (LPSs) of H. influenzae and N. meningitidis, as well
as pneumolysin produced by S. pneumoniae [15]. TLR4 requires the adaptor protein MD2 to bind
to the lipophilic part of LPSs, which activates intracellular signaling and leads to a host immune
response to invading pathogens [16–19]. TLR9 is localized in the endosomal compartments of cells. It is
specialized in detecting bacterial un-methylated single-stranded DNA—more specifically, unmethylated
cytosine–guanosine-containing oligonucleotide (CpG-DNA). TLR9 requires the DNA-degrading
enzyme DNase to sense single-stranded DNA [16,18,20]. It has been observed that S. pneumoniae,
H. influenzae, and N. meningitidis can activate species-specific patterns of TLR4 and TLR9 [21].
Genetic factors are major determinants of human susceptibility to infectious diseases. A common
type of genetic variation is single-nucleotide polymorphisms (SNPs), which, in immune genes such
as TLRs, are involved in the susceptibility, severity, and outcome of different bacterial and viral
infections [22]. Two well-studied functional SNPs of TLR4 (rs4986790) and TLR9 (rs187084) were
included in this study. The polymorphism of TLR4 Asp299Gly impairs TLR4-mediated LPS signaling
and results in decreased LPS-stimulated NFκB activity [23]. In our previous study, we found that
this polymorphism increases the risk of nasopharyngeal colonization of H. influenzae and Moraxella
catarrhalis in healthy Finnish children [24]. This polymorphism is also associated with septic shock [25],
respiratory syncytial virus (RSV) bronchiolitis [26], sepsis [27], and urinary tract infection (Table 1).
However, previous studies have also shown that the TLR4 polymorphism does not increase the risk of
meningococcal or pneumococcal diseases such meningitis or sepsis [28–30]. The polymorphism TLR9
rs187084 is associated with streptococcal infections and tuberculosis, as well as autoimmune disorders
and cancers [31–33].
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Table 1. Functions of the analyzed single-nucleotide polymorphisms (SNPs) and allele frequencies in
the African population.
Target SNP ID Location
Allele
Frequency in
the African
Population
Allele
Frequency in
this Study
Potential Effect and
Reported Associations
TLR4 rs4986790
Chromosome 9
In gene
896A > G
A: 0.93
G: 0.07
A: 0.91
G: 0.09
Diminished responsiveness:
M. catarrhalis and
H. influenzae, pneumococcal
and meningococcal
infections, septic shock,
and respiratory syncytial
virus (RSV)
TLR9 rs187084
Chromosome 3
Promoter area
−1486T > C
T: 0.71
C: 0.29
T: 0.73
C: 0.27
Associated with
autoimmune disorders and
cancers, RSV, Acinetobacter
baumannii, tuberculosis,
and streptococcal infections
There are other TLR4 and TLR9 SNPs that are associated with BM. In one study, it was found
that the carriage of one or both mutant alleles in TLR4 896A > G and TLR9-1237 increases the risk of
hearing loss in BM survivors. Another study found that BM patients who carried the minor allele
T of TLR9 (rs352140) developed seizures more often than those without. It has also been reported
that there is an association between TLR9 SNPs and susceptibility to BM, specifically meningococcal
meningitis. Although an association between the TLR9 polymorphism rs187084 and BM has not yet
been described, previous studies with other TLR9 polymorphisms indicate that this polymorphism
may also play a role in BM susceptibility or outcome [3,34,35].
Thus, our goal was to identify the functional gene polymorphisms of TLR4 and TLR9 that affect
the susceptibility to and severity and outcomes of BM in Angolan children.
2. Materials and Methods
2.1. Subjects
This study was a part of two prospective randomized clinical trials of children with BM in the
Luanda Children’s Hospital (Hospital Pediátrico David Bernardino) Luanda, Angola. The studies
were approved by the Luanda Children’s Hospital ethics committee. We assessed all children aged 2
months to 15 years presenting with signs suggestive of BM. A child was enrolled if their CSF appeared
cloudy, was positive by Gram staining, or showed >50 leukocytes/mm3. The exclusion criteria included
previous neurological abnormalities or hearing impairment, immunosuppression except for HIV
infection, active tuberculosis, known hepatic disease, or pre-treatment with more than one dose of
parenteral antibiotic. The patients were included in the study after informed consent was provided by
their guardians [36,37]. Oral informed consent was also obtained from the guardians of the controls.
The study cohort consisted of 241 children with confirmed BM, children with compatible symptoms
and signs of BM and a positive CSF Gram stain, latex agglutination, culture, or PCR or a positive
blood culture, and of whom a filter paper blood sample was available. The median age was 15 months
(interquartile range (IQR) 6, 43; range 1–161 months). Of these children, 47% (n = 114) were females
and 53% (n = 127) males. The detailed information of the patients is shown in the Table 2, and numbers
less than 241 refer to only those whose information was available. The diagnosis was made by the
attending physician, and the diagnostic criteria have been described previously [38]. The control group
consisted of 265 Angolan children with no history of BM, and with no active infection. The median
age of the control group was 66 months (IQR 42, 114; range 0–186 months). The gender of the control
group was registered in 191 cases; 37% (n = 71) were female and 63% (n = 120) were male. The control
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samples were collected after a Sunday service (n = 72), at other pediatric wards (n = 74), at the surgery
ward (n = 18), at surgery outpatient visits (n = 59), or at vaccination visits (n = 42). The patients were
enrolled from 2005 to 2008 and from 2012 to 2017, and the control group children were enrolled in 2008
and 2017.
Table 2. Background, clinical, and laboratory data of patients.
Characteristics TotalSubjects 1 N (%)
Value
Distribution Range
Age in months, median (IQR) 241 - 15 (6, 43) 1–161
Male 241 127 (53%) - -
Weight (kg), median (IQR) 241 - 9 (6.8, 12.7) 3.6–36
Clinical features
Fever (◦C), mean (SD) 239 50 2 37.5 (0.99) 35–40
Length of hospital stay in days, median (IQR) 3 158 - 12 (10, 36.05) 6–63
Poor general condition 238 142 (60%) - -
Convulsion in hospital 235 155 (66%) - -
Altered consciousness during admission 237 166 (70%) - -
Additional focus of infection present 232 69 (30%) - -
Dyspnea 238 125 (53%) - -
Glasgow coma score, median (IQR) 213 - 12 (9, 15) 3–15
Blantyre coma score, median (IQR) 212 - 4 (3, 5) 1–5
Fatal outcome 241 63 (26%) - -
Severe neurological sequelae at discharge 177 24 (14%) - -
Laboratory tests, median (IQR)
CRP (mg/L) 207 - 161 (128, 161) 7–340
Glucose in CSF (mg/dL) 4 233 - 10 (5.5, 19.55) 0.5–270
Protein in CSF (mg/dL) 4 118 - 201.15 (136.2, 269) 10.2–1806
Leukocytes in CSF (/mm3) 4 241 - 1560 (414.5, 3590) 8–32,400
Blood leukocytes (/µL) 182 - 15.3 (10.2, 21.4) 1.23–57
MMP-8 in CSF (ng/mL) 92 - 854.2 (250, 1220) 3.74–3560
1 The total number of subjects was 241; numbers less than 241 refer only to those whose information was available.
2 Axillary temperature, fever if ≥38.0 ◦C. 3 The length of the hospital stay excludes patients with fatal outcome.
4 Measured at admission. IQR, interquartile range (lower, upper); SD, standard deviation; CRP, C-reactive protein;
CSF, cerebrospinal fluid; MMP-8, matrix metalloproteinase-8.
2.2. Laboratory Tests, Clinical Findings, and Severity Factors of BM
Microscopic examination, leukocyte counts, and glucose, matrix metalloproteinase-8 (MMP-8),
and protein concentration measurements were performed for CSF specimens taken at admission. CSF
was cultured on blood and chocolate agar plates and bacteria were identified by Gram stain or standard
bacteriological phenotypic methods. When available, a latex agglutination test (Pastorex Meningitis,
Bio-Rad Laboratories Inc., Marne-La-Coquette, France) was conducted if >100 leukocytes/mm3 were
present and bacterial culture was negative. Whenever possible, the remaining CSF sample was stored at
–80 ◦C and shipped for PCR identification to the National Institute of Health, Lisbon, Portugal, or later
to the Centre for Respiratory Diseases and Meningitis (CRDM), National Institute for Communicable
Diseases (NICD), Johannesburg, South Africa [37]. Concentrations of MMP-8 were determined with a
time-resolved immunofluorometric assay (Medix Biochemica, Espoo, Finland).
In a previous study in the Paediatric Hospital of Luanda, Pelkonen et al. identified prognostic
factors for poor outcomes in BM [5]. In this study, we compared the genotype distributions of TLR4
and TLR9 between the previously identified prognostic factors for poor outcomes in BM. The studied
laboratory variables were levels of glucose, protein, leukocytes, and MMP-8 in CSF at admission.
In addition, the highest level of C-reactive protein (CRP) and leukocytes in blood were analyzed.
Additionally, the following factors were assessed: Poor general condition, level of consciousness,
convulsions, and Glasgow and Blantyre coma scores at admission. In addition, neurological sequelae
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(other than ataxia), deafness, blindness, other focuses of infection during hospital stay, and fatal
outcomes were analyzed.
2.3. DNA Isolation
Blood samples for the genetic studies of the BM patients (n = 241) and the first set of controls
(n = 74) were collected with a dried blood spot (DBP) collection card (PerkinElmer 226 Sample Collection
Device, PerkinElmer, Waltham, MA, USA), as these patients had blood collected for other purposes as
well. Later, the second control set of DNA samples (n = 191) were taken from healthy individuals with
SK-1S DNA buccal swabs (Isohelix, Harrietsham, Kent, UK) to avoid pain in sampling.
Genomic DNA was extracted with the QIAamp® mini DNA extraction kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol for extracted genomic DNA. DNA concentrations
were determined by a spectrophotometer (NanoDrop 1000, Thermo Scientific, Waltham, MA, USA).
The entire eluted DNA sample was stored at −20 ◦C for further examination.
2.4. Genotyping
TLR4 896A > G (rs4986790) and TLR9-1486T > C (rs187084) were determined by high-resolution
melting analysis (HRMA). The analyses were performed using LightCycler 480 version 5.1 (Roche,
Basel, Switzerland) with a SensiFAST HRMA melting master kit (Bioline, London, UK). The method
for TLR4 rs4986790 genotyping has been published in detail previously [39].
The primers for TLR4 rs4986790 (forward 5′-ACCATTGAAGAATTCCGATTAGCA-3′,
reverse 5′-CCAGGGAAAATGAAGAAACATTTG-3′) and for TLR9 rs187084 SNP (forward
5′-TTATTCCCCTGCTGGAATGTCA-3′, reverse 5’-CTGTACTGGATCCTGGGGATG-3′) were designed
with the Primer-BLAST design tool (National Center for Biotechnology Information (NCBI),
U.S. National Library of Medicine, Bethesda, MD, USA) and were ordered from Sigma-Aldrich
(Saint Louis, MO, USA). Amplicon sizes were 95 bp (TLR4) and 72 bp (TLR9).
In each reaction, the volume was 20 µL and consisted of 3 µL of genomic DNA (approximately
8 ng/µL) and 17 µL of master mix, including 10 µL of melting master dye and 0.2 µM of forward
and reverse primers. The master mix provided a final concentration of 3 mM of MgCl2. The HRMA
reactions were run at 95 ◦C for 10 min, followed by 44 cycles of amplification at 95 ◦C for 10 s, at 60 ◦C
for 10 s, and at 72 ◦C for 15 s. After PCR, the final melting cycle conditions were outlined by LightCycler:
First heating to 95 ◦C and holding for 1 min, followed by cooling to pre-hold temperature (40 ◦C).
The melting interval for collecting fluorescence was set from 60 to 95 ◦C (a ramp rate of 0.02 ◦C/s).
In each run, three DNA samples with known (sequenced) genotypes of TLR4 (rs4986790) and TLR9
rs187084 were used as controls.
Additionally, all samples with an atypical HRMA difference curve or melting peak were analyzed
by Sanger sequencing in the Finnish Institute for Molecular Medicine (FIMM), Helsinki, Finland.
2.5. Statistical Analyses
Statistical analyses were performed using the JMP Pro software for Windows, version 14
(SAS Camous Drive, Cary NC, USA) and IBM SPSS Statistics for Windows, version 25 (IBM Corp.,
Armonk, NY, USA). Categorical variables are described using numbers (n) and percentages (%)
and bivariate analyses were performed with Fisher’s exact test. Continuous data are described by
using means and 95% confidence intervals (CIs) or medians and IQRs as appropriate. SNP data
and continuous data were compared using a Mann–Whitney U test if the data were not normally
distributed. Multivariate analysis (i.e., binominal logistic regression analysis) was performed for
the clinical features if p < 0.05. Poor general condition, convulsions during admission, and weight
below two standard deviations (SDs) were used as covariates. A p-value of <0.05 was considered
statistically significant. A Hardy–Weinberg (HWE) test was used to calculate the observed genotype
distribution in the control population. The differences in the numbers of patients are due to missing or
non-determined data.
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3. Results
3.1. Detection of Pathogens and Laboratory Values
Bacterial etiology was confirmed from all 241 BM cases. Of these, 136 (56%) were caused
by Gram-positive bacteria and 105 (44%) by Gram-negative bacteria. The bacterial distribution is
presented in Figure 1. The three most common pathogens identified were S. pneumoniae (n = 108,
44.8%), N. meningitidis (n = 43, 17.8%), and H. influenzae (n = 38, 15.8%). The overall case fatality rate
was 26% (n = 63). The highest fatality rate was 34% (n = 37) in pneumococcal meningitis, whereas the
lowest fatality rate was 5% (n = 8) in meningococcal meningitis.
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Figure 1. Distribution of the pathogens in the study population. 1 Salmonella spp. (n = 5), Proteus spp.
(n = 6), Citrobacter freundii (n = 2), Escherichia coli (n = 2), Klebsiella spp. (n = 6), Shigella spp. (n = 1),
Enterobacter spp. (n = 1), and unknown Gram-negative bacteria (n = 1). 2 Staphylococcus aureus (n = 3)
and unknown Gram-positive bacteria (n = 13).
The laboratory findings of the BM patients are presented in Table 2. In brief, the median
concentration of CRP was 161 mg/L and of leucocytes was 15.3/µL in the blood, while in the CSF,
the concentration of glucose was 10 mg/dL, of protein was 201 mg/dL, of leucocytes was 1560/mm3,
and of MMP-8 was 854 ng/mL.
3.2. Association between Susceptability to BM and the Gene Polymorphisms of TLR4 and TLR9
The frequencies of the studied TLR4 and TLR9 polymorphisms in the control group are presented
in Table 3. Additionally, altogether, four subjects had another TLR4 polymorphism in the area of
interest in the TLR4 gene. The frequency of the TLR4 rs201050092 (902T > C) minor genotype (CT)
was 0.01 in both groups. When the HWE was calculated for TLR4 (rs4986790) and TLR9 (rs187084),
no deviations were found in the control group (p = 0.099 and p = 0.957) or in the patient group (p = 0.079
and p = 0.931).
The frequency of the variant genotypes AG and GG in TLR4 was significantly higher in patients
with H. influenzae meningitis than in the controls (OR, 2.5; 95% CI, 1.2–5.4; p = 0.021), whereas the
frequency of the variant genotypes of CT and CC in TLR9 was significantly lower in patients with
H. influenzae meningitis than in the controls (OR, 0.4; 95% CI, 0.2–0.9; p = 0.036). No differences in the
genotypes of TLR4 and TLR9 were found in patients with BM caused by other pathogens in comparison
with the control children. The haplotype analyses between TLR4 and TLR9 did not show significant
associations in patients with BM.
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Table 3. Genotype frequencies of the analyzed SNPs TLR4 rs4986790 (AA compared to AG and GG)
and TLR9 rs187084 (TT compared to CT and CC) with the causative bacteria of bacterial meningitis
(BM).
Gram-Negative Bacteria Gram-Positive Bacteria
H. Influenzae N. Meningitidis OtherBacteria S. Pneumoniae
Other
Bacteria
Control
Group
TLR4
rs4986790
AA (%) 26 (68.4) 40 (93.0) 22 (91.6) 92 (85.2) 23 (82.1) 224 (84.5)
AG (%) 10 (26.3) 2 (4.6) 2 (8.3) 15 (13.9) 5 (17.9) 37 (13.9)
GG (%) 2 (5.3) 1 (2.3) 0 1 (0.9) 0 4 (1.5)
Total n 38 43 24 108 28 265
HWE 0.44 0.002 0.831 0.661 0.604 0.099
p-Value 1 0.022 0.164 0.549 0.999 0.784 Ref.
OR (95% CI) 2.5 (1.2–5.4) 0.4 (0.1–1.4) 0.5 (0.11–2.2) 1 (0.5–1.7) 1.2 (0.43–3.3)
TLR9
rs187084
TT (%) 27 (71.1) 21 (50.0) 14 (58.3) 57 (55.3) 13 (46.4) 136 (51.7)
CT (%) 8 (21.1) 20 (47.6) 9 (37.5) 45 (43.7) 13 (46.4) 106 (40.3)
CC (%) 3 (7.9) 1 (2.4) 1 (4.2) 5 (4.9) 2 (7.1) 21 (8.0)
Total n 38 42 24 103 2 263
HWE 0.065 0.133 0.764 0.296 0.572 0.957
p-Value 0.036 0.869 0.670 0.819 0.692 Ref.
OR (95% CI) 0.4 (0.2–0.9) 1.1 (0.6–2.1) 0.76 (0.33–1.8) 0.9 (0.6–1.5) 1.2 (0.57–2.7)
1 Bivariate analysis was calculated by Fisher exact test between BM and control group. OR, odds ratio; CI,
confidence interval.
3.3. Association between Laboratory Values, Severity Factors of BM, and the TLR4 and TLR9 Polymorphisms
No associations were observed between the laboratory values or between the defined severity
factors of BM and the studied SNPs across the entire study group. Table 4 shows the values from
children who had meningitis caused by Gram-negative bacteria. The children who had meningitis
caused by Gram-negative bacteria and who had a variant type of TLR4 had significantly lower levels
of MMP-8 (226 ng/mL (IQR, 64, 556) in their CFS at admission than those who had the AA genotype
(1133 ng/mL (IQR, 834, 1642); p = 0.004). At the time of discharge, the children who carried a variant
type of TLR4 had a higher risk of ataxia (adjusted OR, 12.91; 95% Cl, 1.52–109.80; p = 0.019) and other
neurological sequelae (adjusted OR, 11.85; 95% Cl, 1.07–131.49; p = 0.044).
In the Gram-positive BM group, children who were carriers of a variant type of TLR4 (AG or GG)
had lower levels of CSF glucose (7.5 mg/dL (IQR, 3.4, 12 03); p = 0.038) and blood leukocytes (9.5/µL
(IQR, 5.06, 17.30); p = 0.024) at admission than those who had the AA genotype (Table S1).
A TLR9 variant genotype seemed to play a different role to a TLR4 variant type. In the bivariate
analysis between the factors and TLR9 polymorphisms, carriers of a TLR9 variant genotype (CT or CC)
had a lower risk of ataxia (OR, 0.22; 95% Cl, 0.06–0.84; p = 0.029) and other neurological sequelae (OR,
0.15; 95% Cl, 0.02–1.26; p = 0.049) at the time of discharge. After multivariate analysis, the differences
were not statistically significant (Table 5).
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Table 4. Associations between the TLR4 (rs4986790) polymorphism and the laboratory values and
severity factors of Gram-negative bacterial meningitis (BM).
Clinical Features
TLR 4
OR (95% Cl) p-Value
AA AG and GG
Poor general condition 1 40 (46.0) 11 (64.7) 2.15 (0.73–6.35) 0.191
Convulsions during admission 1 32 (37.6) 8 (50.0) 1.66 (0.57–4.85) 0.409
Level of consciousness 1
Normal 37 (43.5) 5 (29.4) -
0.544Altered 43 (50.6) 11 (64.7) -
Coma 5 (5.9) 1 (5.9) -
Glasgow coma score (<12) 1 31 (38.3) 9 (56.3) 2.07 (0.70–6.14) 0.266
Other focus of infection during hospital stay 49 (56.3) 10 (58.8) 1.11 (0.39–3.18) 0.999
Pneumonia during hospital stay 31 (35.2) 8 (47.1) 1.63 (0.57–4.66) 0.415
Outcome
Fatal 15 (17.0) 6 (35.3) 2.66 (0.85–8.30) 0.102
Severe neurological sequelae 3 5 (6.9) 2 (18.2) 2.98 (0.50–17.68) 0.231
Deafness 3 5 (8.6) 0 (0.0) 0.91 (0.84–0.99) 0.999
Blindness 3 1 (1.4) 2 (20.0)
17.5 (1.42–215.21)
- 2
0.039
(0.99) 2
Any neurological sequelae (no ataxia) 3 6 (8.3) 4 (40.0)
7.33 (1.31–33.41)
11.85 (1.07–131.49) 2
0.017
(0.044) 2
Ataxia 3 12 (16.9) 7 (70.0)
11.47 (2.59–50.80)
12.91 (1.52–109.80) 2
0.001
(0.019) 2
Laboratory variables, median (IQR)
CRP (mg/L)
161.00
(131.5,
172.0)
(n = 77)
160.00
(70.5, 161.0)
(n = 13)
- 0.183
CSF glucose 1 (mg/dL)
10.40
(4.80,
22.10)
(n = 88)
9.30
(5.15, 26.63)
(n = 16)
- 0.786
CSF protein 1 (mg/dL)
191.85
(124.9,
257.15)
(n = 46)
187.05
(146.48,
282.55)
(n = 6)
- 0.748
CSF leukocytes 1 (/mm3)
1612.50
(970.00,
3830.50)
(n = 88)
1440.00
(857.50,
1440.00)
(n = 17)
- 0.748
Blood leukocytes (/µL)
16.11
(11.04,
24.35)
(n = 73)
13.96
(8.23, 22.20)
(n = 12)
- 0.434
CSF MMP-8 1 (ng/mL)
1132.57
(834.04,
1641.75)
(n = 30)
225.93
(63.56, 556.31)
(n = 6)
- 0.004
1 Determined/measured at admission. 2 Determined at the time of discharge. 3 Adjusted OR; binominal logistic
regression analysis. Poor general condition, convulsions during admission, and weight below 2 SD were used
as covariates. IQR, interquartile range (lower, upper); CRP, C-reactive protein; CSF, cerebrospinal fluid; MMP-8,
matrix metalloproteinase-8.
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Table 5. Associations between the TLR9 (rs187084) polymorphism and the laboratory values and
severity factors of Gram-negative bacterial meningitis.
Clinical Features
TLR9
OR (95% Cl) p-Value
TT CT and CC
Poor general condition 1 28 (45.9) 23 (54.8) 1.43 (0.65–3.14) 0.426
Convulsions during admission 1 28 (46.7) 12 (30,0) 0.490 (0.21–1.14) 0.144
Level of consciousness 1
Normal 25 (41.7) 17 (41.5) -
0.928Altered 31 (51.7) 22 (53.7) -
Coma 4 (6.7) 2 (4.9) -
Glasgow coma score (<12) 1 23 (41.1) 17 (42.5) 1.06 (0.47–2.41) 0.999
Other focus of infection during hospital stay 35 (57.4) 23 (54.8) 0.90 (0.41–1.99) 0.841
Pneumonia during hospital stay 24 (38.7) 15 (35.7) 0.88 (0.39–1.98) 0.838
Outcome
Fatal 12 (19.4) 9 (21.4) 1.14 (0.43–3.00) 0.808
Severe neurological sequelae 2 7 (14.0) 0 (0.0)
0.86 (0.77–0.96)
0.00 (0.00–0.00) 3
0.039
0.999 2
Deafness 2 3 (7.7) 2 (7.4) 0.96 (0.15–6.17) 0.999
Blindness 2 3 (3.1) 0 (0.0) 0.94 (0.87–1.01) 0.279
Any neurological sequelae (no ataxia) 2 9 (18.0) 1 (3.2)
0.15 (0.02–1.26)
0.17 (0.02–1.47) 3
0.049
(0.107)
Ataxia 2 16 (32.7) 3 (9.7)
0.22 (0.06–0.84)
0.25 (0.06–1.04) 2
0.029
(0.057) 2
Laboratory variables, median (IQR)
CRP (mg/L)
161.00
(108.5,173.3)
(n = 50)
161.00
(133.0, 161.0)
(n = 39)
- 0.814
CSF glucose (mg/dL) 1
8.75
(4.73,
17.33)
(n = 60)
16.40
(7.88, 25.53)
(n = 38)
- 0.252
CSF protein (mg/dL) 1
189.10
(125.50,
275.00)
(n = 31)
189.40
(131.15,
249.35)
(n = 20)
- 0.549
CSF leukocytes (/mm3) 1
1518.50
(850.00,
3125.00)
(n = 62)
1725.00
(990.00,
5607.50)
(n = 42)
- 0.991
Blood leukocytes (/µL)
15.74
(10.89,
26.05)
(n = 52)
15.63
(10.71, 21.14)
(n = 32)
- 0.826
CSF MMP-8 (ng/mL) median
958.28
(319.46,
1496.89)
(n = 20)
1187.47
(866.80,
1632.45)
(n = 16)
- 0.278
1 Determined/measured at admission. 2 Determined at the time of discharge. 3 Adjusted OR; binominal logistic
regression analysis. Poor general condition, convulsions during admission, and weight below 2 SD were used
as covariates. IQR, interquartile range (lower, upper); CRP, C-reactive protein; CSF, cerebrospinal fluid; MMP-8,
matrix metalloproteinase-8.
In the Gram-positive BM group, no differences were observed between the studied TLR9 SNPs,
clinical features, and laboratory values (Table S2).
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4. Discussion
In the present study, we analyzed the frequencies of the different genotypes of two functional
SNPs of TLR4 and TLR9 in Angolan children with BM caused by different bacteria, and we compared
this to controls matched for age and ethnicity. We observed a significant difference between patients
with BM caused by H. influenzae and the controls. In addition, patients with meningitis caused by
Gram-negative bacteria who were carriers of a variant TLR4 genotype had an increased risk of ataxia
and other neurological sequelae than those with a wild-type TLR4 genotype. To the best of our
knowledge, this is the first study to show that genetic variation in TLR4 and TLR9 is associated with
H. influenzae meningitis in Angolan children.
TLR4 SNP rs4986790 is one of the most studied SNPs and its variant genotypes AG and GG are
associated with several infectious diseases. We recently reported that Finnish adults who are carriers
of the variant genotypes of this TLR4 SNP had significantly lower concentrations of serum IL-6, IL-12,
and IL-17A than those who are carriers of the wild-type of TLR4 [40]. It is known that TLR4 variants
are associated with hypo-responsiveness to LPS, and humans with these polymorphisms are more
susceptible to infections caused by Gram-negative bacteria, and the disease is often more severe [10].
One study found a connection between TLR4 SNPs and invasive pneumococcal sepsis [41]. Another
study on survivors of meningococcal sepsis revealed an increased susceptibility between the TLR4
rs4986790 heterozygous mutation and N. meningitidis infection [30,42]. However, other studies have
shown contradictory results [43–45].
The effect of the TLR9 SNP rs187084 has not yet been reported for pneumococcal or meningococcal
infections, although it is associated with other bacterial infections. In puerperal women, an association
between the TLR9 polymorphism and Streptococcus pyogenes has been observed [46]. The TLR9
polymorphism also has a functional significance in sepsis and multiple organ failure in patients with
blunt trauma injury [47]. Furthermore, an association between persistent Streptococcus aureus nasal
carriage and the TLR9 polymorphism has been found [48].
In this study, we found a correlation between the TLR4 and TLR9 polymorphisms and H. influenzae
meningitis in Angolan children. This finding suggests that genetic variations of TLR4 rs4986790 and
TLR9 rs187084 play a role in the susceptibility to H. influenzae meningitis. Moreover, the variant
genotypes AG and GG of TLR4 rs4986790 are associated with increased susceptibility to H. influenzae
meningitis. In contrast, the variant genotypes CT and CC of TLR9 rs187084 seem to decrease the
susceptibility to H. influenzae meningitis. We observed no associations between the analyzed TLR4 and
TLR9 polymorphisms with other BM-causing pathogens, such as S. pneumoniae and N. meningitidis.
We also compared the allele frequencies of TLR4 rs4986790 and TLR9 rs187084 with African and
European populations. In this study, the major A and minor G allele frequencies of TLR4 rs4986790
in BM patients were 0.91 and 0.09, which are similar to those observed in the African population
(A, 0.93; G, 0.07) and the European population (A, 0.94; G, 0.06) in the 1000 Genomes Project [49].
However, when comparing the genotype frequencies (AA, 0.68; AG, 0.26; GG, 0.05) in patients with
H. influenzae meningitis to the African population (AA, 0.87; AG, 0.12; GG, 0.009) and the European
population (AA, 0.89; AG, 0.10; GG, 0.006), significant differences were found. These differences were
only found in patients with BM caused by H. influenzae, but not by S. pneumoniae or N. meningitidis.
In addition, there was no such observation in the controls of this study [49]. The major T and minor G
allele frequencies of TLR9 rs187084 were 0.73 and 0.27 in BM patients, which are similar to the African
population (T, 0.71; C, 0.29) but different from other populations, such as the European population
(T, 0.57; C, 0.43). Although the genotype frequencies of TLR9 in patients with BM caused by all
pathogens are similar to that in the African population (TT, 0.514; CT, 0.387; CC, 0.098) in the 1000
Genomes Project, a significant difference was found in patients with H. influenzae meningitis (TT, 0.711;
CT, 0.211; CC, 0.079) [50].
One of the most important diagnostic tools in BM is CSF analysis. A confirmed diagnosis of
BM can be made when the bacterial culture of CSF is positive. Low glucose and elevated leukocyte
count, protein levels, and MMP-8 and -9 in CSF can indicate severe BM [51–53]. However, in this study,
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we observed no association between the analyzed SNPs and the levels of glucose, protein, or leukocytes
in the CSF, or of CRP and leukocytes in the blood. In a previous study in Latin America, our group
showed that elevated MMP-8 levels in CSF predict poor disease outcomes in BM caused by H. influenzae,
N. meningitidis, and S. pneumoniae [52]. In this study, we observed that the variant types of TLR4 are
associated with significantly lower levels of MMP-8 in children who had BM caused by Gram-negative
bacteria, including H. influenzae and N. meningitidis. Since MMP-8 plays a central role in regulating
tissue destruction, remodeling, and immune responses, this finding supports the broad role for the
genetic variation of TLR4 in clinical outcomes of children with BM caused by Gram-negative bacteria.
In this study, patients who had meningitis caused by Gram-negative bacteria and who were carriers
of the variant TLR4 genotypes had higher risk of ataxia and other neurological sequelae than those
with the wild-type TLR4 genotype. More association and functional studies on the polymorphisms of
TLRs are needed to reveal the exact mechanism causing the differences in clinical course and to obtain
genetic traits that can be used for patient profiling and management of patients with a CNS infection.
Identifying the risk factors for severe disease has been, historically, the first step toward helping
patients. If the risk cannot be eliminated (such as age) or manipulated (such as undernutrition), the next
step is to identify the mechanisms by which a disease causes harm. By understanding the underlying
pathophysiology, one might then search for better treatment options. For instance, if a disease causes
an exaggerated innate immune response, then this can be targeted in order to improve the course and
outcome of the disease.
There are some limitations of our study. Although the total number of confirmed BM patients was
relatively large, the number of individual causative pathogens such as H. influenzae and N. meningitidis
was limited. Therefore, it is possible that we could have missed some weak associations. In this
study, only one SNP of TLR4 and TLR9 was tested, and the possible effects of the other SNPs in the
two genes on the susceptibility to and outcome of bacterial meningitis should also be kept in mind.
In addition, the possible influence of genetic drift from the enrolled population on the results cannot
be completely excluded.
5. Conclusions
The polymorphisms of TLR4 rs4986790 (896A > G) and TLR9 rs187084 (-1486T > C) were
associated with susceptibility to H. influenzae meningitis in Angolan children. The variant genotypes
of TLR4 seemed to be associated with an increased risk of H. influenzae meningitis, whereas the
variant genotypes of TLR9 seemed to be associated with a decreased risk of H. influenzae meningitis.
Furthermore, a variation in TLR4 may increase the risk of the development of certain neurological
sequelae after BM caused by Gram-negative bacteria. However, we observed no correlation between
the analyzed SNPs and the other causative pathogens of BM. It should be noted that these results are
valid only for children in Angola.
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